Market Overview - The biopharmaceutical sector experienced a decline of 0.7% on January 27, with the nearshore protein leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Top Gainers in Biopharmaceutical Sector - Hualan Ting (301207) saw a closing price of 26.05, with a significant increase of 11.61% and a trading volume of 563,900 shares, totaling a transaction value of 1.421 billion yuan [1] - Sanofi Guojian (688336) closed at 63.53, up 10.93%, with a trading volume of 201,400 shares and a transaction value of 1.270 billion yuan [1] - Wanzhe Co. (000534) closed at 30.80, increasing by 8.45%, with a trading volume of 318,400 shares and a transaction value of 958 million yuan [1] Top Decliners in Biopharmaceutical Sector - Nearshore Protein (688137) closed at 49.50, down 6.95%, with a trading volume of 39,100 shares and a transaction value of 192 million yuan [2] - Watson Bio (300142) closed at 13.49, decreasing by 6.84%, with a trading volume of 1,628,800 shares and a transaction value of 2.193 billion yuan [2] - Sanyuan Gene (920344) closed at 25.37, down 6.52%, with a trading volume of 32,200 shares and a transaction value of 81.8541 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 821 million yuan from institutional investors, while retail investors saw a net inflow of 243 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Junshi Biosciences (688180) had a net inflow of 1.93 million yuan from institutional investors, but saw a net outflow of 9.328 million yuan from speculative funds [3] - Wanzhe Co. (000534) experienced a net inflow of 51.5191 million yuan from institutional investors, with a net outflow of 1.2819 million yuan from speculative funds [3] - Zhixiang Jintai (688443) had a net inflow of 18.0619 million yuan from institutional investors, while speculative funds saw a net outflow of 636.35 million yuan [3]

近岸蛋白首次公开发行股票的发行费用总额为12,078.67万元，其中，承销保荐费用9,842.17万元。 近岸蛋白首次公开发行股票募集资金总额为186,298.25万元，扣除发行费用后募集资金净额为174,219.58 万元。该公司最终募集资金净额较原计划多24,219.58万元。近岸蛋白于2022年9月26日披露的招股说明 书显示，其拟募集资金150,000.00万元，拟分别用于诊断核心原料及创新诊断试剂产业化项目、研发中 心建设项目和补充流动资金。 中国经济网北京1月27日讯 近岸蛋白(688137.SH)今日股价下跌，截至收盘，该股报49.50元，跌幅 6.95%。该股目前处于破发状态。 近岸蛋白于2022年9月29日在上交所科创板上市，发行价格为106.19元/股，发行股票数量为1,754.3860 万股，保荐人（主承销商）为民生证券股份有限公司（现为"国联民生证券股份有限公司"），保荐代表 人为王璐、黄立超。 (责任编辑：马欣) ...

Core Viewpoint - The company, Suzhou Nearshore Protein Technology Co., Ltd., has shown a mixed financial performance with a significant increase in revenue but a notable decline in net profit, indicating potential challenges ahead in profitability despite growth in sales [2]. Group 1: Financial Performance - As of January 26, Nearshore Protein's stock price increased by 6.40%, with a trading volume of 233 million yuan [1]. - For the period from January to September 2025, the company achieved a revenue of 112 million yuan, representing a year-on-year growth of 21.48% [2]. - The net profit attributable to shareholders for the same period was -28.86 million yuan, reflecting a year-on-year decrease of 58.06% [2]. Group 2: Shareholder and Market Activity - As of November 10, the number of shareholders for Nearshore Protein was 6,056, a decrease of 0.53% from the previous period [2]. - The average number of circulating shares per shareholder increased by 0.53% to 5,395 shares [2]. - The company has distributed a total of 70.18 million yuan in dividends since its A-share listing [3]. Group 3: Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included several funds, with Huashang Lexiang Flexible Allocation Mixed A being the third-largest shareholder, holding 604,700 shares, a decrease of 14,800 shares from the previous period [3]. - Huashang Zhenxuan Return Mixed A ranked fourth with 463,100 shares, down by 9,450 shares [3]. - Huashang Yuanjian Value Mixed A increased its holdings by 137,800 shares, ranking fifth with 444,000 shares [3].

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

| 买入营业部名称 | 买入金额(万元) | | --- | --- | | 华泰证券股份有限公司江西分公司 | 1443.68 | | 开源证券股份有限公司西安西大街证券营业部 | 991.08 | | 天风证券股份有限公司浙江分公司 | 894.20 | | 中信建投证券股份有限公司福州东街证券营业部 | 809.16 | | 国新证券股份有限公司长沙韶山路证券营业部 | 718.75 | | 卖出营业部名称 | 卖出金额(万元) | | 方正证券股份有限公司武汉中山大道证券营业部 | 1606.99 | | 中航证券有限公司吉安广场北路证券营业部 | 919.31 | | 华泰证券股份有限公司南京郑和中路证券营业部 | 756.73 | | 民生证券股份有限公司苏州分公司 | 572.32 | | 机构专用 | 515.60 | （文章来源：证券时报网） 1月13日近岸蛋白（688137）收盘价49.60元，收盘上涨15.43%，全天换手率17.78%，振幅21.29%，成交 额2.91亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 证券时报·数据宝统计显示，上榜的前五大买卖营业部 ...

从资金流向上来看，当日生物制品板块主力资金净流入3.99亿元，游资资金净流出6286.66万元，散户资 金净流出3.36亿元。生物制品板块个股资金流向见下表： 证券之星消息，1月13日生物制品板块较上一交易日上涨1.15%，康乐卫士领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920575 | 康乐卫士 | 11.99 | 29.90% | 35.12万 | | 4.02亿 | | 688331 | 荣昌生物 | 114.46 | 20.00% | 21.22万 | | 23.69亿 | | 688137 | 沂岸蛋白 | 49.60 | 15.43% | 5.81万 | | 2.91亿 | | 920344 | 三元基因 | 28.45 | 11.44% | 6.86万 | | 1.94亿 | | 301047 | 义翘神州 | 82.02 | ...

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the six-month moving average, with a change of -0.03% [1] - The total trading volume of A-shares today is 185.05 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 168 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Nearshore Protein (近岸蛋白) with a deviation rate of 19.69% and a price increase of 19.99% [1] - Erkang Pharmaceutical (尔康制药) with a deviation rate of 17.97% and a price increase of 19.14% [1] - Wanbang Pharmaceutical (万邦医药) with a deviation rate of 12.41% and a price increase of 12.85% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Bo Wen Technology (博闻科技) with a deviation rate just above the average [1] - Jilin Expressway (吉林高速) and Teda Investment (泰达股份) also show minor deviations [1] Additional Notable Stocks - Other stocks with notable performance include: - Deer Medical (鹿得医疗) with a price increase of 13.63% and a deviation rate of 11.86% [1] - Chuaning Biological (川宁生物) with a price increase of 12.84% and a deviation rate of 10.67% [1] - New Zhi Biological (新芝生物) with a price increase of 14.33% and a deviation rate of 10.66% [1]

Group 1 - The core point of the article highlights the significant performance of the stock "近岸蛋白" (Nearshore Protein) on the STAR Market, with its price reaching 51.56 yuan and a trading volume of 1.09 billion yuan, indicating a strong market interest [2] - Among the stocks on the STAR Market, 279 stocks were reported to be rising, with 9 stocks experiencing an increase of over 10%, including Nearshore Protein, which rose by 19.99% [2] - Conversely, 315 stocks were reported to be declining, with notable decreases in stocks such as 航天环宇 (Aerospace Universe), 国科军工 (National Science Military Industry), and 坤恒顺维 (Kunheng Shunwei), which fell by 15.38%, 12.31%, and 11.59% respectively [2] Group 2 - In terms of capital flow, Nearshore Protein experienced a net outflow of 2.4189 million yuan on the previous trading day, with a total net outflow of 5.2999 million yuan over the last five days [3] - The latest margin trading data as of January 12 shows that the total margin balance for Nearshore Protein is 60.0453 million yuan, with a financing balance of 60.0453 million yuan, reflecting a decrease of 577.89 thousand yuan, or 8.78%, from the previous trading day [3] - Over the past 10 days, the total margin balance has increased by 1.7593 million yuan, representing a growth of 3.02%, with the financing balance also growing by 3.02% during this period [3]

Core Viewpoint - The company, Suzhou Nearshore Protein Technology Co., Ltd., has shown a mixed financial performance with a significant increase in revenue but a notable decline in net profit for the period ending September 2025 [2]. Group 1: Financial Performance - As of November 10, 2025, Nearshore Protein reported a revenue of 112 million yuan, representing a year-on-year growth of 21.48% [2]. - The net profit attributable to the parent company was -28.86 million yuan, reflecting a year-on-year decrease of 58.06% [2]. - Cumulative cash dividends since the company's A-share listing amount to 70.18 million yuan [3]. Group 2: Shareholder and Market Activity - As of December 31, 2025, the number of shareholders decreased by 0.53% to 6,056, while the average circulating shares per person increased by 0.53% to 5,395 shares [2]. - On December 31, 2025, the financing balance for Nearshore Protein was 56.94 million yuan, accounting for 4.35% of the market capitalization, which is below the 10% percentile level over the past year [1]. - The top ten circulating shareholders include several funds, with notable changes in holdings, such as Huashang LeXiang Flexible Allocation Mixed A reducing its shares by 1,480 shares [3].

证券代码：688137 证券简称：近岸蛋白 公告编号：2026-001 苏州近岸蛋白质科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/28 | | | | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 10 月 15 日~2026 4 月 | 13 日 | 年 | | 预计回购金额 | 1,000万元~2,000万元 | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | □为维护公司价值及股东权益 | | | | 累计已回购股数 | 0万股 | | | | 累计已回购股数占总股本比例 | 0% | | | | 累计已回购金额 | 0万元 | | | | 实际回购价格区间 | 0元/股~0元/股 | | | 一、回购股份的基本情况 公司于 2024 年 9 月 26 日召开第二届董事会第六次临时会议，并于 2024 年 10 月 ...